Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Wednesday

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of ($1.66) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Sage Therapeutics Trading Down 1.6 %

SAGE stock opened at $10.81 on Tuesday. The firm has a 50 day moving average of $11.27 and a 200-day moving average of $16.58. The company has a market cap of $650.55 million, a price-to-earnings ratio of -1.29 and a beta of 0.90. Sage Therapeutics has a 12-month low of $9.73 and a 12-month high of $37.17.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SAGE. JPMorgan Chase & Co. cut shares of Sage Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $18.00 to $12.00 in a research report on Thursday, July 25th. Oppenheimer lowered their target price on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a report on Thursday, April 18th. HC Wainwright reissued a “neutral” rating and issued a $25.00 price target on shares of Sage Therapeutics in a report on Thursday, July 25th. Scotiabank decreased their price objective on Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating on the stock in a research note on Thursday, July 25th. Finally, TD Cowen downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $16.00 to $10.00 in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $33.25.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.